

Pembrolizumab KEYNOTE-054

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



Pembrolizumab KEYNOTE-054

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Skin Cancers

Therapeutic Indication: Adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection

Experimental Arm: Pembrolizumab

Control Arm: Placebo



